Nov 16, 2020
Wainamics in the Semi-Finals Round for the XPRIZE Rapid COVID Testing
Wainamics, together with our partners, is developing a Low Cost Swab to Answer, Rapid COVID Test and was selected as an XPRIZE Rapid Covid Testing semi-finalist. The simple to use system consists of our low cost disposable cartridge that contains all required reagents, providing swab to answer results.
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovativecompetition models to solve the world’s grandest challenges. Active competitions include the$20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 MillionANA Avatar XPRIZE, the $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling,XPRIZE NextGen Mask Challenge and $5 Million XPRIZE Rapid COVID Testing. For moreinformation, visit xprize.org.
Nov 9, 2020
Wainamics would like to congratulate Jennifer Doudna and Emmanuelle Charpentier for winning the 2020 Nobel Prize in chemistry. They developed CRISPR-Cas9, a revolutionary gene-editing tool that can change the DNA of plants and animals with extraordinary precision. Wainamics is excited to be working on a project with Jennifer and the Innovative Genomics Institute to develop microfluidic cartridges that implement the CRISPR assay.
Oct 30, 2020
Wainamics Working on NIH RADx Project to Develop a Rapid COVID Test
Wainamics has teamed up with strategic partners to develop a low cost COVID-19 rapid test that is easy to use and requires no special handling. This project is one of forty-six companies selected for Phase 1 of the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Tech program. The RADx Tech program is accelerating the development, commercialization, and implementation of technologies for COVID-19 testing. The simple system delivers results in less than 45 minutes and features a disposable cartridge for use in a compact, low-cost instrument. The Wainamics cartridge contains all required reagents that provides swab to answer results.
CEO Ming Tan emphasized the importance of accessible and reliable tests to a safe return to everyday activities. She commented, “Together with our capabilities in cartridge development and assay integration and the expertise of our partners, our team is capable of rapidly developing a robust, scalable, low-cost point-of-care system.”
This project is supported by the NIH Rapid Acceleration of Diagnostics (RADx ) program and has been funded in whole or in part with federal funds from National Heart, Lung and Blood Institute, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Grant No. 3U54HL143541-02Sl.
Apr 28, 2020
Ming Tan, Ph.D. and Wainamics were recently featured on the Mammoth Interviews series.
Aug 5, 2019
The device Wainamics developed for Purdue University spin-off OmniVis was featured on NPR news.
Wainamics is invited to the Microfluidics for Hematology (µHematology 2020) in Chicago, IL to present "A Novel Point-of Care Blood Coagulation Factor VIII Test Device for Hemophilia Management" and a poster on "Point-of-Care Diagnostic Testing Device using Electrochechemical-Based Detection."
Mar 1-4, 2020
Wainamics exhibited at the 27th International Molecular Medicine Tri-Conference in San Francisco, CA. Ming Tan, Ph.D. presented "Point-of-Care, Quantitative Procalcitonin Test Using Electrochemistry Sensors" as part of the Enabling Point-of-Care Technologies track.
Oct 7-9, 2019
Wainamics presented a poster on "Critical Components for Lab-on-a-Chip Product Development" at Lab-on-a-Chip & Microfluidics World Congress in San Diego, CA.
Aug 6-8, 2019
Wainamics exhibited at the 2019 AACC Annual Scientific Meeting and Clinical Lab Expo in Anaheim, CA.
Mar 11-13, 2019
Wainamics exhibited at the 26th International Molecular Medicine Tri-Conference in San Francisco, CA.